Neuland Laboratories , a prominent player in the pharmaceutical API manufacturing sector, has scheduled its Q2 FY26 earnings announcement and conference call for November 7, 2025. This announcement comes as the company prepares to share its financial results for the quarter and half-year ended September 30, 2025.

Key Details of the Earnings Call

The company has confirmed that the financial results will be made available on their official website, www.neulandlabs.com , coinciding with the announcement.

Company Overview

Neuland Laboratories has established itself as a significant player in the pharmaceutical industry over the past four decades. Here are some notable achievements of the company:

• Operates cGMP manufacturing facilities
• Serves customers in nearly 80 countries
• Developed over 300 processes and 100 APIs
• Filed approximately 990+ regulatory filings globally
• Maintains 72 active US Drug Master Files (DMFs)

Regulatory Compliance and Certifications

Neuland Labs' commitment to quality and reliability is evident through its extensive list of certifications, including:

• U.S. FDA
• TGA (Australia)
• EDQM (EU)
• German Health Authority
• ANVISA (Brazil)
• EMA (EU)
• Cofepris (Mexico)
• KFDA (Korea)
• PMDA (Japan)
• CFDA (China)
• FSI "SID & GP" Russia
• Health Canada
• ISO 9001, ISO14001, OHSAS18001, and ISO 27001

This upcoming earnings call presents an opportunity for investors and analysts to gain insights into Neuland Laboratories' performance and future outlook. Interested parties can register for the call using the provided Diamond Pass link.

For those seeking more information about Neuland Laboratories or wishing to participate in the earnings call, the company has provided the following contact details:

• For general inquiries: ir@neulandlabs.com
• For specific queries: Ravi Udeshi at ravi.udeshi@in.ey.com

As the pharmaceutical industry continues to evolve, Neuland Laboratories' Q2 FY26 results may offer valuable insights into the company's position in the market and its strategies for growth in the coming quarters.

Neuland Laboratories Ltd , a prominent player in the pharmaceutical industry, has unveiled a significant restructuring of its executive leadership, set to take effect from April 1, 2026. The Board of Directors approved these changes on September 23, 2025, subject to shareholder approval, aiming to align the organization's growth plans and balance short-term and long-term objectives.

Key Leadership Changes

Mr. Sucheth Rao Davuluri

• Currently serving as Vice Chairman & CEO
• Will transition to the role of Executive Vice Chairman
• New focus areas:
  • Long-term planning
  • Enterprise risk management
  • Stakeholder management
  • Internal audit oversight
  • CSR initiatives through the Neuland Foundation

Mr. Saharsh Rao Davuluri

• Presently the Vice Chairman & Managing Director
• Will be re-designated as CEO & Managing Director
• Will assume responsibility for day-to-day operations
• Brings experience in building the CMS (Contract Manufacturing Services) business and understanding of client and market needs

Transition Period and Reporting Structure

• Transition period: Immediate to March 31, 2026
• Purpose: Ensure seamless handover of operational responsibilities
• Reporting: Both Mr. Sucheth Davuluri and Mr. Saharsh Davuluri will continue to report directly to the Executive Chairman, Dr. D. R. Rao

Strategic Implications

• Timing: Crucial period for Neuland Laboratories
• Company transformation:
  • From generic API manufacturer to specialty API plus CDMO (Contract Development and Manufacturing Organization) player under Mr. Sucheth Davuluri's leadership
  • Elevation as a reputed CDMO through Mr. Saharsh Rao's efforts in building the CMS business
• Expected benefits:
  • Better fulfillment of commitments
  • Maintained trust and goodwill with customers
  • Enhanced focus on immediate operational needs and long-term strategic goals

Shareholder Approval and Implementation

• Board approval: Obtained
• Shareholder approval: Required before formal implementation
• Implementation date: April 1, 2026

Neuland Laboratories' decision to announce these changes well in advance demonstrates a commitment to transparency and smooth transition in its leadership structure. As the pharmaceutical industry continues to evolve, this strategic move positions Neuland to adapt and grow in a competitive market landscape.